An Open-label, Three Period, Fixed Sequence Study to Assess the Effect of a Single Dose of BIA 5 1058 400 mg on Warfarin Pharmacokinetics in Healthy Subjects Under Fasting Conditions
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Zamicastat (Primary) ; Warfarin
- Indications Heart failure; Pulmonary arterial hypertension
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors BIAL - Portela C S.A.
- 12 Aug 2021 New source identified and integrated ClinicalTrials.gov: (US National Institutes of Health: (NCT04994119).
- 11 Dec 2020 New trial record
- 21 Oct 2020 Results presented at the CHEST Annual Meeting 2020 by Annual Meeting of the American College of Chest Physicians